Furthermore, pharmacological activators of Nrf2 are already in clinical development for treating traumatic brain injury, stroke, and cancer and could also be tested in NDDs (Robledinos-Antón et al., 2019; Zhou et al., 2020a). Here, NFE2L2 is linked to cancer.